# US 2022/0276243 A1 · Inflammatory bowel disease diagnosis method, diagnosis probe and diagnosis kit

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276243 A1
- Document ID: US20220276243A1
- Status: Published application
- Kind: A1
- Application number: 17/631,117
- Filed: 2020-08-25
- Published: 2022-09-01
- Earliest claimed: 2019-08-29
- Assignees: Tohoku University
- Applicants: Tohoku University
- Inventors: Tsuyoshi SHIRAI; Hiroshi FUJII; Tomonori ISHII; Hideo HARIGAE; Yoichi KAKUTA; Atsushi MASAMUNE; Tomoyuki MUTOH
- Web page: https://patentgrep.com/patent/US20220276243A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/54: Determining the risk of relapse
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are a novel determination method, diagnostic probe, and diagnostic kit for inflammatory bowel disease. A method for determining inflammatory bowel disease includes measuring an anti-endothelial cell protein C receptor antibody (anti-EPCR antibody) in a sample collected from a subject.

## Claims

### Claim 1

A method for determining inflammatory bowel disease, comprising measuring an anti-endothelial cell protein C receptor antibody (anti-EPCR antibody) in a sample collected from a subject.

### Claim 2 (depends on 1)

The method according to claim 1, comprising
contacting the sample collected from the subject with an endothelial cell protein C receptor (EPCR),
measuring the amount of the anti-endothelial cell protein C receptor antibody (anti-EPCR antibody) in the sample, and
determining that the subject has inflammatory bowel disease when the measured value is higher than a reference value.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the determining comprises determining:
whether inflammatory bowel disease is present,
a risk of developing inflammatory bowel disease, severity of inflammatory bowel disease,
a preventive effect on inflammatory bowel disease,
a therapeutic effect on a patient with inflammatory bowel disease,
whether inflammatory bowel disease has recurred,
a risk of recurrence of inflammatory bowel disease, whether inflammatory bowel disease has relapsed, or
a risk of relapse of inflammatory bowel disease.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the sample is blood, serum, or plasma.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

### Claim 6

A diagnostic probe for inflammatory bowel disease comprising an endothelial cell protein C receptor (EPCR).

### Claim 7

A diagnostic kit for inflammatory bowel disease comprising an endothelial cell protein C receptor (EPCR).